VIEW IN BROWSER
 

EDITOR'S NOTE: Big4Bio newsletters will not be published Nov 23rd-27th; they will resume distribution on Monday, Nov 30th.

November 17, 2026
Regional intelligence on Drugs, Diagnostics, Devices & Digital Health
* may need subscription to view
Big4Bio CEO Weekly - Q&A Life Sciences Leaders
BIG4BIO CEO WEEKLY Q&A:
Oren Gilad, Ph.D., President & CEO, Aprea Therapeutics
In this Q&A, Gilad discusses what differentiates APR-1051 from earlier WEE1 inhibitors, the biomarker strategy behind Aprea's approach to precision oncology, milestones the company is working toward, and realities of leading a clinical-stage biotech through scientific and financial uncertainty. More

Press Releases

  • Biocon: Gets U.S. FDA Approval for Pebrilzo (pertuzumab-qcay) Injection, a Biosimilar to Perjeta, Expanding Its Oncology Portfolio More
  • Cognition Therapeutics: CTAD Poster Highlighting Screening Efficiencies With p-Tau217 in the Ongoing Phase 2 START Study More
  • Cognito: Pivotal Phase 3 Results for Spectris AD, a Non-Invasive, At-Home Approach for Alzheimer’s Treatment, Backed by ADDF Investment More
  • Corxel US: Presents Full Phase 2 Results for CX11 in Adults With Overweight and Obesity at ObesityWeek 2026 More
  • Feinstein Institutes: Dr. Kevin J. Tracey Receives Cold Spring Harbor Laboratory Double Helix Medal More
  • Helus Pharma: Positive Topline Results From Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder More More More* More*
  • Kos Biotechnology Partners and FORTH: Strategic Partnership to Advance Biotechnology Innovation in Greece More
  • Novo: Presents Preclinical and Human Data Suggesting a Role for Amylin and Calcitonin Receptor Activation in Preserving Bone During Weight Loss at ObesityWeek More
  • Novo: Wegovy Resulted in a BMI Reduction of 10% or More in Almost 80% of Children With Obesity Aged 6 to Under 12, Compared to 0% With Placebo in Step Young Trial, Published in the New England Journal of Medicine More
  • Nuvation Bio: Presented Additional Long-Term Follow-Up Data From Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting More
  • Precision Neuroscience and Team Gleason: Partner to Give the ALS Community a Voice in Brain–Computer Interface Development More
  • Regeneron: Libtayo (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications More
  • SELLAS Life Sciences: Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia More More
  • Teva: U.S. FDA Approves IGALMI as First At-Home Acute Treatment for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults More

Financial News

  • ADM Tronics: Second Quarter of Fiscal Year 2027 Results More
  • Dana Foundation: 2026 Neuroscience & Society Champion Award Recipients More
  • Interpace Biosciences: Third Quarter 2026 Financial and Business Results More
  • More on J&J Buying Eye Disease Biotech Ollin Biosciences for Up to $3.3B More* More* More More
  • Palatin: Fiscal First Quarter 2027 Financial Results and Business Update More
  • SCIENTURE: Q3 2026 Results With Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY More
  • Vaso Corporation: Financial Results for Third Quarter of 2026 More

Media/Misc Coverage

  • Big4Bio CEO Weekly Q&A: Oren Gilad, Ph.D., President & CEO, Aprea Therapeutics More
  • Biotech & Pharma Updates | November 16, 2026 More
  • Strategic Intent: Praxis CEO on “Unlearning,” AI and Launching Two Neuroscience Drugs at Once Podcast
  • Subscribe to LifeSci Startup for Updates on US Startups More
evotec | Your next chapter in drug discovery starts with a conversation. Meet Evotec at JPM Week 2027. Book a meeting >

Career Moves

Slone Partners Places Farhad Ghavami as Chief Executive Officer at SeqCenter
Learn More  →
  • ICYMI: Milestone Cuts 20% of Staff With CMO, CFO Exiting Leadership Roles More* More
  • ICYMI: More on Cellectis Shedding 70% of Workforce as Part of In Vivo Pivot More More
  • OPPORTUNITY: Director of Compliance, Remote More
  • OPPORTUNITY: Head of Market Development & Strategy, California More
  • OPPORTUNITY: Senior Vice President, Regulatory Affairs & Quality Assurance, Boston More
  • Slone Partners: Doing More With Less - Building the Right Nonprofit Leadership Team in a Resource-Constrained Environment More
  • Slone Partners: Leading Through AI - The New Playbook for Healthtech Executives More
  • Tris Pharma: Named a BioSpace 2027 Best Places to Work Winner More
On Your Mark 2027 | Every event of JPM Week. Jnauary 11-14, San Francisco. List your event - free. onyourmark.bio

Events

Note: Events may be in any Big4Bio region or virtual
Spotlight Event: Biotech Showcase, Jan 11-13
Learn More  →
  • Patient Pathways (Use code 26B4B10 for 10% off) Nov 17-20
  • Pricing & Contracting WEST (Use code 26B4B10 for 10% off) Dec 7-8
  • Trade and Channel Strategies (Use code 26B4B10 for 10% off) Dec 8-10
  • Advancing Drug Development Forum Dec 10
  • ABD Capital Connect JPM Healthcare Week Jan 11-12
  • Biotech Showcase Jan 11-13
  • 45th Annual J.P. Morgan Healthcare Conference Jan 11-14
  • PEGS AI Summit Jan 18-21
  • PepTalk 2027 Jan 18-21

SEE FULL EVENT SCHEDULE AT THE BIOCALENDAR

Companies

DISCOVER COMPANIES
Big4Bio: NYC Life Science Company Directory
Locate a specific company or explore new companies in life science.
Explore our Company Directory Provided courtesy of
BioPharmGuy Logo

NYC Sponsors


Follow us


Spotlights       Get Featured       Company Directory      News       Contact       Subscribe

You are receiving this email because you signed up for one of our newsletters at Big4Bio.com, signed up at one of our partner or sponsor events, or given as a gift subscription by your firm or organization. Unsubscribe

Big4Bio:NYC, all rights reserved 2026

© 2026 Big4Bio, a division of BigBio Communications. All rights reserved.